Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
In December 2025, Parliament was presented with a document of long-term national importance: the 2025 Strategic Review on the ...
Friends of Commerce reflects on 2025 - a year defined by expanded global delivery, deepened strategic partnerships, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback